Type to search

Enhertu Granted Breakthrough Therapy Designation in US for Patients with HER2-positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-based Regimens | Pharmtech Focus
Imfinzi Plus Chemotherapy Tripled Patient Survival at Three Years in the CASPIAN Phase III Trial in Extensive-stage Small Cell Lung Cancer | Pharmtech Focus